ModifiedUnitedHealthcarePolicy CS061ID.B

Implanted Electrical Stimulator for the Spinal Cord (Idaho only)

Medical policy governing coverage and medical necessity of implanted spinal cord stimulators (SCS) and dorsal root ganglion (DRG) stimulation for Idaho members, including Idaho Medicaid Plus.

Policy Summary

PayerUnitedHealthcare

PolicyImplanted Electrical Stimulator for the Spinal Cord (Idaho only)

Policy CodePolicy CS061ID.B

Change TypeRevisions to covered indications and documentation requirements

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionRefer to InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion for medical necessity and ensure complete, legible medical record documentation supporting requests.

SourceLink

POLICY UPDATE CHANGES

Revised list of proven and medically necessary conditions; replaced 'painful lower limb diabetic neuropathy' with 'painful diabetic neuropathy'.

Replaced language indicating DRG stimulation is proven and medically necessary for refractory CRPS when performed according to FDA labeled indications with language removing the 'refractory' qualifier.

Added explicit requirements that the patient's medical record must contain documentation that fully supports medical necessity, including history, exam, and pertinent diagnostic test results.

Updated Clinical Evidence and References sections; archived previous policy version CS061ID.A.

Updated reference link to reflect current policy title for Gastrointestinal Disorders Diagnostic Procedures (Idaho only).

CS061ID.BPolicy identifier

IdahoGeographic application

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

inv-01: SCS - Medically Necessary Indications

Implanted electrical spinal cord stimulators (SCS) are proven and medically necessary for the following conditions in certain circumstances when performed according to FDA-labeled indications and InterQual criteria:

Covered Indications (SCS): Complex regional pain syndrome (CRPS)

Must meet InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion

Covered Indications (SCS): Painful diabetic neuropathy

Must meet InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion

Covered Indications (SCS): Failed back surgery syndrome

Must meet InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion

inv-02: SCS - Not Medically Necessary / Unproven

SCS is considered unproven and not medically necessary for the following indications due to insufficient evidence of efficacy:

Not Medically Necessary (SCS): Chronic intractable back pain without prior spine surgery

Insufficient evidence; no adequate studies for primary low back pain or HF-EMC systems for this indication

Not Medically Necessary (SCS): Refractory angina pectoris

Insufficient evidence for SCS in refractory angina in this policy excerpt

inv-03: DRG - Medically Necessary and Not Medically Necessary

Dorsal root ganglion (DRG) stimulation coverage and exclusions:

Covered Indications (DRG): Complex regional pain syndrome (CRPS I, CRPS II)

Must be performed according to FDA-labeled indications, contraindications, warnings, precautions and InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion

Not Medically Necessary (DRG): DRG stimulation is unproven and not medically necessary for all other conditions (e.g., cancer-related neuropathic pain; postherpetic neuralgia; diabetic peripheral neuropathy; central neuropathic pain due to MS, stroke, ischemia, or amputation)

Hayes and systematic reviews report very low quality or insufficient evidence for other indications

inv-04: Evidence synthesis (no formal coverage algorithm provided in excerpt)

Key evidence findings, safety signals, patient selection considerations, and limitations that inform the coverage stance:

Key efficacy findings: ACCURATE randomized trial: greater treatment success with DRG versus SCS at 3 months (81.2% vs 55.7%); multiple systematic reviews and cohorts report many patients achieving ≥50% pain reduction in selected populations.

ACCURATE trial and systematic reviews support DRG efficacy for CRPS and focal neuropathic pain

Safety and complications: Reported complications include lead fracture/migration, IPG pocket pain, lead defects, infections (pooled overall ~2.82%; implant infections ~4.80%), and occasional permanent nerve injury during revisions; infection risk is lower during trial than at implant stage.

Pooled infection rates and cohort/registry reports

Patient selection and trial: DRG/SCS are generally used for focal neuropathic pain in patients who have failed pharmacologic and nonpharmacologic therapies; guidelines and experts recommend a stimulation trial and psychosocial screening prior to permanent implant.

Most studies enrolled patients refractory to other treatments; ASRAPM and NICE recommend trial and psychosocial assessment

inv-05: Evidence summaries and external guidance

External guideline positions and regulatory context that inform coverage decisions (informational):

VA/DoD guidance: 2022 VA/DoD Clinical Practice Guideline recommended against SCS for patients with low back pain.

May inform exclusionary decisions for primary low back pain indications

NICE (Evoke) evaluation: 2020 NICE Medtech briefing found limited but methodologically sound evidence for the Evoke SCS system; experts considered it likely comparable to other systems.

Informational regarding device comparability

NICE (Senza HF10) recommendations: NICE (2019) recommends HF10 therapy for chronic neuropathic back or leg pain ≥50 mm VAS at least six months after back surgery despite conventional medical management, following a successful trial and multidisciplinary assessment.VAS >= 50 mm; >= 6 months after back surgery

Specifies selection and timing criteria used by NICE

Coverage determinations in this policy distinguish between indications supported by adequate evidence and those considered unproven or not medically necessary. The policy explicitly lists SCS and DRG uses that are proven and medically necessary when performed according to FDA-labeled indications and InterQual clinical criteria, and it identifies specific conditions for which the technologies are unproven and not medically necessary due to insufficient evidence of efficacy. Examples of unproven/not medically necessary SCS indications include chronic intractable back pain without prior spine surgery and refractory angina pectoris. For DRG, the policy states that stimulation is unproven and not medically necessary for all conditions other than CRPS. Replacement of a battery/generator is allowed only when the device is malfunctioning, not repairable, and out of warranty. Providers should refer to the InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion for the full medical necessity criteria that govern coverage decisions.

Available evidence for dorsal root ganglion (DRG) stimulation supports its use primarily for focal neuropathic conditions—most consistently CRPS—while data for other neuropathic pain etiologies remain limited and low quality. Systematic reviews and meta-analyses include small, heterogeneous studies (many industry-sponsored) and report positive but inconclusive findings for diverse neuropathic conditions; pooled responder rates vary by pain location and study design. Hayes and other reviews conclude the effectiveness and safety of DRG stimulation for neuropathic pain related to cancer, postherpetic neuralgia, diabetic peripheral neuropathy, and central neuropathic pain (e.g., MS, stroke, ischemia, amputation) are currently unknown or unsupported by adequate evidence.

For informational context, the 2022 VA/DoD Clinical Practice Guideline for low back pain recommended against the use of spinal cord stimulation (SCS) for patients with low back pain. This guideline statement is cited in the policy as a relevant external guidance point that informed discussions about the evidence base for SCS in primary low back pain.

UnitedHealthcare considers implanted electrical spinal cord stimulators not medically necessary for chronic intractable back pain without prior spine surgery. The policy cites the absence of adequate trial evidence for SCS in non‑surgical low back pain and references evidence reviews that find support for SCS primarily in persistent post‑surgical back pain rather than for primary nonsurgical chronic back pain.

Evidence syntheses and guideline summaries report limited benefit of SCS for some somatic low back pain presentations. Meta-analyses and systematic reviews include small studies with heterogeneous populations and report inconsistent outcomes; many authors conclude that SCS/DRG may help selected, highly screened patients who have failed other therapies, but overall evidence quality is low and further randomized trials are needed. These limitations support restricting coverage for primary nonsurgical low back pain and emphasizing careful patient selection where neuromodulation is considered.

The North American Spine Society (NASS) 2020 evidence‑based guideline found no studies adequate to address electrical stimulation for low back pain. This finding is cited in the policy as evidence of an evidence gap and is used to inform determinations that electrical stimulation is insufficiently supported for primary low back pain indications.

Procedure, Device and Product Codes

CPT codesCPT

63650	Percutaneous implantation of neurostimulator electrode array, epidural.
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array.

HCPCS (L-codes)HCPCS

L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.
L8695	External recharging system for battery (external) for use with implantable neurostimulator, replacement only.

FDA product codes referencedmixed

LGW	FDA product code referenced for PMA (SCS devices)
GZB	FDA product code referenced for PMA (SCS devices)
GZF	FDA product code referenced for 510(k) process
PMP	FDA product code referenced for DRG stimulation devices

Provider Requirements, Prior Authorization and Documentation

Prior Authorization

Prior Authorization and Coding Reference

Prior authorization required. Coverage is governed by medical necessity criteria and applicable federal, state, and contractual plan terms. UnitedHealthcare uses InterQual® CP: Procedures, Spinal Cord Stimulator (SCS) Insertion to assess medical necessity; authorization must follow InterQual and payer-specific requirements prior to implantation or replacement procedures.

Verify prior authorization requirements with UnitedHealthcare before scheduling SCS/DRG implantation or replacement
Provide InterQual-based documentation as requested for clinical review
Confirm plan-specific coding and billing guidance when submitting authorization requests

Documentation Required

Trial Stimulation and Documentation

A stimulation trial is recommended before permanent implantation except when clinically contraindicated (for example, anginal pain per guidance). Document the trial process, duration, objective and patient-reported response, and any complications. Include results of the trial in the authorization and medical record to support medical necessity for a permanent implant.

Conservative Care and Patient Selection Preconditions

inv-33: Documented failure of conservative therapies

Most studies and systematic reviews describe DRG and SCS patient populations as having failed prior conservative therapies; documented failure of these therapies is implied as part of appropriate patient selection.

Prior conservative therapy: Documented failure of appropriate pharmacologic and nonpharmacologic conservative therapies prior to trial of neuromodulation

Study populations and systematic reviews commonly required prior treatment failure; providers should document prior therapies and response

inv-34: Failure of conventional medical management

When applicable (per NICE guidance for HF10/Senza), failure of conventional medical management and timing thresholds apply:

Failure of conventional medical management: >= 6 months since back surgery with persistent neuropathic back or leg pain despite conventional medical management>= 6 months post-surgery

Clinical Background and Rationale

Spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation are implantable neuromodulation therapies that deliver electrical stimulation to neural targets to reduce chronic neuropathic pain and improve quality of life. SCS systems typically place epidural leads in the dorsal epidural space to modulate dorsal column pathways, while DRG stimulation targets the dorsal root ganglion to provide more focal coverage of dermatomal pain. Clinical trial evidence supports the use of SCS for selected indications such as complex regional pain syndrome (CRPS), painful diabetic neuropathy, and failed back surgery syndrome when performed according to FDA labeling and applicable clinical criteria. DRG stimulation has demonstrated benefit for CRPS (I and II) in controlled and observational studies but the body of evidence for other neuropathic etiologies is small and of low quality; most published DRG series enrolled patients who had failed prior pharmacologic and nonpharmacologic interventions and emphasize the need for trial stimulation and careful patient selection.

Definitions and Terminology

Replacement battery/generator — replacement criteria

When replacement is appropriateReplacement is appropriate when the individual's existing battery/generator is malfunctioning, cannot be repaired, and is no longer under warranty.

ContextApplies to replacement of a previously implanted electrical stimulator device.

Documentation impliedMedical record should document malfunction, attempted repair (if any), and warranty status to support replacement request.

Treatment success (as used in ACCURATE)

Definition of treatment success (ACCURATE)Composite endpoint: ≥50% decrease in pain score from pre-implant baseline at 3 months without any stimulation-related neurological deficits.

Timepoint

Frequency and Replacement Limits

Replacement battery/generator — frequency/fleet rule

Allowed replacement ruleReplacement of an implanted battery/generator is allowed when the device is malfunctioning, cannot be repaired, and is no longer under warranty.

ScopeApplies to replacement of previously implanted electrical stimulators (pulse generators/batteries).

Imaging and Diagnostic Test Requirements

Note

Refractory angina studies sometimes used MIBI‑SPECT (contextual)

Some refractory angina studies reported ischemia proven by MIBI‑SPECT; this is mentioned as contextual evidence but the policy does not impose a specific imaging requirement for angina indications.

Vervaat et al. (2020) reported ischemia proven by MIBI‑SPECT in 69% of participants in a refractory angina cohort.
This imaging finding is contextual and not stated as a formal policy imaging requirement.

Note

No specific imaging requirements specified in this excerpt

The policy excerpt does not specify required imaging modalities for SCS/DRG; guidance emphasizes trial stimulation and psychosocial screening rather than routine imaging requirements.

ASRAPM guidance focuses on trial and psychosocial screening rather than mandating imaging.
No specific imaging modality is required by the policy text in the provided excerpt.

Not Covered / Experimental Indications

The policy lists several specific indications and scenarios that are not covered / unproven, including: chronic intractable back pain without prior spine surgery (SCS), refractory angina pectoris (SCS), and DRG stimulation for conditions other than CRPS. Additionally, the effectiveness and safety of DRG stimulation for neuropathic pain etiologies such as cancer‑related neuropathy, postherpetic neuralgia, diabetic peripheral neuropathy outside the labeled setting, and central neuropathic pain (e.g., MS, stroke, ischemia, amputation) are not supported by current evidence. External guideline findings (for example NASS 2020 and VA/DoD 2022) that found insufficient or negative evidence for electrical stimulation in primary low back pain are cited as informational support for these non‑covered indications.

Policy Changes and Revision History

2026-06-01related_policy_update

Updated a related policy reference link to reflect the current policy title for Gastrointestinal Disorders Diagnostic Procedures (Idaho only).

2026-02-01coverage_criteria_revision

Revised coverage rationale: updated list of proven and medically necessary conditions for implanted electrical spinal cord stimulators, replacing 'painful lower limb diabetic neuropathy' with 'painful diabetic neuropathy'.

2026-02-01coverage_criteria_revision

Revised DRG stimulation language to remove the 'refractory' qualifier, stating DRG stimulation is proven and medically necessary for treating complex regional pain syndrome (CRPS I, CRPS II) when performed according to FDA-labeled indications and precautions.

Policy Summary

PayerUnitedHealthcare

PolicyImplanted Electrical Stimulator for the Spinal Cord (Idaho only)

Policy CodePolicy CS061ID.B

Change TypeRevisions to covered indications and documentation requirements

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionRefer to InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion for medical necessity and ensure complete, legible medical record documentation supporting requests.

SourceLink

On This Page

Prior Authorization

Check Plan-Specific Coverage and Authorization

Check plan-specific coverage, authorization, and coding rules prior to providing services. Federal, state, or contractual requirements may mandate coverage or impose different authorization workflows; in case of conflict, those requirements govern.

Confirm member’s benefit plan and any state mandates that affect coverage
Validate whether the requested service requires precertification or alternative review pathways
Follow payer-directed submission portals and documentation checklists

Documentation Required

Medical Record Requirements

The patient's medical record must fully support medical necessity. Required documentation includes relevant medical history, focused physical examination, and results of pertinent diagnostic tests or procedures. Records must be legible, maintained in the patient record, and available upon request.

Include history of present illness, prior treatments (pharmacologic and nonpharmacologic), and response to therapy
Attach imaging, EMG/NCS, or other diagnostic test results when relevant
Provide consultation notes and specialty evaluations used to justify SCS/DRG therapy

Documentation Required

Patient Selection and Psychosocial Screening

Patient selection should follow evidence-based guidance and include psychosocial screening. Use an objective, validated instrument to screen for psychosocial factors (including depression) and document results and any management plan.

Document indication consistent with evidence-based indications (e.g., CRPS, painful diabetic neuropathy, failed back surgery)
Include validated psychosocial screening tool name, results, and any interventions addressing identified issues
Document multidisciplinary input when used for decision-making

Denial Risk

Documentation Insufficiency — Denial Risk

Insufficient or missing documentation may result in denial of authorization or claim payment. Ensure the medical record explicitly addresses prior conservative therapy, trial results (if performed), and rationale for permanent implantation.

Failure to document prior pharmacologic and nonpharmacologic interventions and their outcomes may lead to denial
Absence of trial stimulation documentation (when a trial is recommended) may result in a request for additional information or denial
Incomplete history, physical exam, or missing diagnostic test results increase denial risk

Documentation Required

Documentation Required to Avoid Denial

To avoid denial, include comprehensive documentation: detailed history, focused physical exam findings, prior therapy attempts and durations, diagnostic test results, stimulation trial documentation (if applicable), psychosocial screening results, and justification tying clinical findings to InterQual criteria.

List of prior conservative treatments with dates and outcomes (medications, injections, PT, behavioral therapies)
Stimulation trial report with objective pain and functional measures
Relevant imaging and diagnostic studies and interpretation
Psychosocial screening instrument and results

Note

NICE-Recommended Pathway for HF10 (Informational)

Informational: NICE pathway for HF10 (Senza) — HF10 therapy is recommended as an option for chronic neuropathic back or leg pain after failed back surgery; NICE recommends a successful stimulation trial and multidisciplinary assessment as part of the pathway. Consider this guidance when evaluating HF10 therapy candidates and document trial and team assessment.

HF10 candidates: persistent neuropathic pain ≥50 mm VAS at least six months post-surgery despite conventional medical management
Document successful stimulation trial and multidisciplinary team assessment when HF10 is used

HF10 therapy (Senza) — definition and NICE findings

HF10 (Senza) definitionHigh-frequency 10 kHz spinal cord stimulation therapy delivered by the Senza system; designed to avoid paresthesia while reducing pain and functional disability.

NICE findingsNICE (2019) found HF10 using Senza at least as effective as low-frequency SCS for chronic neuropathic back or leg pain after failed back surgery and noted it avoids paresthesia.

NICE patient selection criteriaNICE recommends HF10 for patients with VAS ≥50 mm at least six months after back surgery despite conventional medical management and after a successful stimulation trial and multidisciplinary assessment.

Note

Policy requires documentation of diagnostic tests but no modality specified

Policy updates reference the need for documentation and pertinent diagnostic test results but do not prescribe particular imaging modality requirements in the revised language.

Revisions emphasize that medical records must include pertinent diagnostic test results to support medical necessity.
The policy does not list modality‑specific imaging requirements in these sections.